Tag: chronic plaque psoriasis

February 28, 2017

Lilly to Present New Data for Taltz (ixekizumab)

At the 75th annual meeting of the American Academy of Dermatology (AAD), Lilly (NYSE:LLY) will share new data on its...
January 10, 2017

Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis

Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported results from an ongoing 3-Part, Phase 3 clinical study of CHS-1420, an adalimumab (HUMIRA)...
January 6, 2017

Dermira Provides Corporate Update

Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of...
January 3, 2017

Dermira Initiates Phase 3 Clinical Program in Acne

Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of...
December 19, 2016

Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis

Cellceutix Corporation is pleased to announce today that 24 of the 25 (all US based) core Phase 2b clinical trial...
December 8, 2016

UCB and Dermira Announce Second CIMZIA® Phase 3 Trial Meets Co-Primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

UCB and Dermira today announced topline results from CIMPASI-1, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and...
November 29, 2016

Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® Biosimilar

Momenta Pharmaceuticals today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate developed in...